1.4 C
Munich
Sunday, January 16, 2022

VINS Bioproducts gets DCGI nod to start clinical trials for VINCOV-19, a therapeutic product against Coronavirus, Health News, ET HealthWorld

Must read

Advertisements

[ad_1]

VINS Bioproducts gets DCGI nod to start clinical trials for VINCOV-19, a therapeutic product against CoronavirusHyderabad based VINS Bioproducts Limited on Monday announced that it will start clinical trials for VINCOV-19, a product for coronavirus treatment, in partnership with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad.

VINCOV-19 is a new therapeutic product developed from immunisation of horses with spike glycoprotein of the inactivated Covid virus to form antibodies and the resultant antisera — the blood serum containing antibodies. This antisera can be injected into humans infected with Covid-19 to neutralise the virus. The results from pre-clinical trials that began in October 2020 have shown that the product has a high neutralising capacity against the coronavirus. The results also suggested passive administration at early stages of the infection to get maximum benefit since neutralising antibodies could block the internalisation of infection to lung cells.

Speaking on the commencement of the clinical trials, approved by the Drugs Control General India (DCGI), Siddharth Daga, Chief Executive Officer, VINS Bioproducts Limited said, “The development of VINCOV-19, in partnership with the Centre for Cellular and Molecular Biology and the University of Hyderabad and under the aegis of the Indian Council of Medical Research (ICMR), is a significant breakthrough in the fight against Covid-19. We feel extremely privileged that we have been able to use our collective resources and expertise in developing this cure and are proud to lead this fight against Covid-19.”

The Clinical Trials of VINCOV-19 to test safety and efficacy will involve over 300 participants, with moderate to severe Covid-19 infection, from across the country.

“The clinical plan is to administer hyperimmune serum to patients with moderate to severe disease according to the published Covid-19 Treatment Guidelines as soon as they are detected positive. This reinforces the idea that the therapeutic strategy, with equine antibodies, will play a significant role in managing Covid-19 and the ensuing pandemic,” the company said in a release.



[ad_2]

Source link

- Advertisement -spot_img

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -spot_img

Latest article